![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 31, 21701-21706, July 30, 1999
,
, andFrom the Department of Physiology, University of Michigan, Ann Arbor, Michigan 48109-0622
| |
ABSTRACT |
|---|
|
|
|---|
Activation of Gq
protein-coupled receptors can either stimulate or inhibit cell growth.
Previously, these opposite effects were explained by differences in the
cell models. Here we show that activation of m3 muscarinic
acetylcholine receptors ectopically expressed in NIH3T3 cells can cause
stimulation and inhibition of growth in the same cell. A clonal cell
line was selected from cells that formed foci agonist dependently
(3T3/m3 cells). In quiescent 3T3/m3 cells, carbachol stimulated DNA
synthesis. In contrast, when 3T3/m3 cells were growing, either due to
the presence of serum or after transformation with oncogenic v-src,
carbachol inhibited growth. This inhibition was not due to reduction of extracellular signal-regulated kinase activity because carbachol induced extracellular signal-regulated kinase phosphorylation in both
quiescent and growing 3T3/m3 cells. Investigating the cell cycle
mechanisms involved in growth inhibition, we found that carbachol
treatment decreased cyclin D1 levels, increased p21cip1
expression, and led to hypophosphorylation of the retinoblastoma gene
product (Rb). Proteasome inhibitors blocked the carbachol-induced degradation of cyclin D1. Effects on p21cip1 were blocked
by a protein kinase C inhibitor. Thus, m3 muscarinic acetylcholine
receptors couple to both growth-stimulatory and -inhibitory signaling
pathways in NIH3T3 cells, and the observed effects of receptor
activation depend on the context of cellular growth.
G protein-coupled receptors are found on virtually all cells and
respond to a wide variety of regulatory molecules to influence differentiated cell functions including contraction, secretion, and ion
transport. With the discovery that the mas oncogene coded for a G protein-coupled receptor (1), much interest has focused on the
potential of these receptors to be involved in malignant transformation. More recently, activating mutations in
thyroid-stimulating hormone receptors have been observed in ~30% of
thyroid adenomas (2), and mutationally activated luteinizing hormone
receptors have been identified in a form of familiar male precocious
puberty that results from hyperplastic growth of Leydig cells (3). Thus, considerable attention has been paid to the growth and
transforming potential of G protein-coupled receptors and their
possible roles in cancer.
It is known that activation of receptors that couple to the
Gq class of G proteins, including the m3 muscarinic
acetylcholine receptor (m3
AchR),1 leads to foci
formation in these cells (4, 5). The ability of these receptors to
mediate an agonist-dependent formation of foci in these
cells has led to them being referred to as "transforming receptors"
(6). However, m3 AchRs and other Gq protein-linked receptors have also been shown to act as agonist-dependent
tumor suppressors in a variety of transformed cells including Chinese hamster ovary cells (7, 8) and pancreatic cancer cells (9). The ability
of these receptors to either stimulate or inhibit cell growth has been
attributed to differences in the cell models. The mechanisms involved
in these cell type-dependent differences in growth response
are unknown (4, 10). This is a difficult problem because these
receptors are able to activate a wide variety of cellular signaling
pathways including increases in intracellular Ca2+,
phospholipids, and cyclic AMP (11). Furthermore, the same receptor may
generate more than one set of intracellular second messengers, and
considerable cross-talk exists between signaling cascades. In addition,
some of the elevated second messengers, such as cyclic AMP, can have
either stimulatory or inhibitory effects on cellular kinase cascades
and cell growth, depending upon the cell model.
The mechanisms responsible for the transforming and growth promoting
effects of G protein-linked receptor activation are currently a highly
active area of investigation. Considerable progress has been made in
elucidating the growth stimulatory effects of these receptors. The
family of mitogen-activated protein kinases (MAPKs) has turned out to
be a central component of G protein-activated intracellular signaling
pathways controlling cell proliferation and transformation (12, 13).
The ability of m3 AchRs to form foci has been shown to be dependent on
ras (5, 14). ras is an upstream activator of MAPKs including the ERKs.
Activated ERKs, in turn, have been described to mediate the expression
of the G1-phase cyclin D1. Cyclin D1/cdk4 complexes
phosphorylate Rb, which ultimately leads to the initiation of the
proliferative response (15). Thus, together, these observations provide
a model for the induction of growth stimulatory and potentially transforming effects by m3 AchR activation.
Little is known concerning the growth-inhibitory mechanisms activated
by these receptors. To investigate the growth-stimulatory and
-inhibitory effects of Gq protein-linked receptors, we
expressed m3 AchRs in NIH3T3 cells. Our studies confirmed that agonist
treatment of m3 AchR-transfected cell populations leads to the
formation of foci in a subset of receptor-bearing cells. As expected,
agonist treatment of quiescent populations of these focus-competent
cells stimulated DNA synthesis. However, when the same focus-competent cells were growing in the presence of serum, agonist treatment induced
a profound transient inhibition of DNA synthesis. Furthermore, when
these cells were fully transformed by v-src, activation of m3 AchRs inhibited cell growth even under conditions of serum starvation. Carbachol-induced inhibition of DNA synthesis was paralleled by an increase in p21cip1, a decrease in cyclin
D1 and E levels, and Rb hypophosphorylation. Together, these data
suggest that the effects of activation of m3 AchRs on cell
proliferation can be either stimulatory or inhibitory within the same
cell model and are influenced by the context of cellular growth.
Materials--
The construction of the pTEJ-8 expression vector
bearing human m3 AchR cDNA has been described previously (16). The
plasmid bearing oncogenic v-src was a kind gift from Dr. Richard Jove (University of South Florida College of Medicine, Tampa, FL). Polyclonal antibodies to cyclin D1 and E, p21cip1, cdk4,
and ERK1/2 were obtained from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA), and the Anti-ACTIVETM MAPK antibody was from Promega
(Madison, WI). Monoclonal antibody to Rb was obtained from PharMingen
(San Diego, CA). Peroxidase-labeled donkey anti-rabbit and sheep
anti-mouse immunoglobulin were purchased from Amersham Pharmacia
Biotech. Carbachol and TPA were obtained from Sigma Chemical Co. The
PKC inhibitor GF109203X (bisindolylmaleimide) was from LC Laboratories
(Woburn, MA). The proteasome inhibitors PSI
(N-benzyloxycarbonyl-Ile-Glu-(O-t-Bu)-Ala-leucinal)
and LLnL (N-acetyl-Leu-Leu-norleucinal) were purchased from
Peptide Institute Co. (Louisville, KY) and Sigma Chemical Co.,
respectively. Dulbecco's modified Eagle's medium, calf serum, fetal
bovine serum (FBS), penicillin, streptomycin, amphotericin B, and
LipofectAMINE were obtained from Life Technologies, Inc.
Tissue Culture--
The mouse NIH3T3 fibroblast cells (obtained
from American Type Culture Collection, Manassas, VA) were grown in
Dulbecco's modified Eagle's medium supplemented with 10% calf serum,
penicillin, and streptomycin.
Foci Formation--
NIH3T3 cells were transfected with 5 µg of
pTEJ8-m3AchR using LipofectAMINE and following the manufacturer's
recommended protocol. The day after transfection, the cells were
replated into three new dishes. One dish was cultured in the presence
of 100 µM carbachol, another dish was cultured in the
presence of 0.8 mg/ml G418, and one dish was cultured in the absence of
carbachol or G418. Foci were scored after 2-3 weeks. Individual foci
were isolated with the aid of cloning cylinders and then selected in
the presence of 0.8 mg/ml G418 to eliminate nontransfected cells. For
replating assays, receptor-bearing cells were mixed with wild-type
NIH3T3 cells at a ratio of 1:1000, and 105 cells were
plated in a 35-mm dish. Cells were cultured in the presence or absence
of 100 µM carbachol, and foci were scored after 2-3 weeks.
N-[3H]methylscopolamine Binding--
The m3 Ach
receptor binding assay was performed exactly as described previously
(16).
Measurement of DNA Synthesis--
DNA synthesis was estimated by
measurement of [3H]thymidine incorporation into
trichloroacetic acid-precipitable material. Cells growing in the
absence or presence of 10% FBS were treated with carbachol (100 µM) for 24 h or as indicated, and
[3H]thymidine (0.1 µCi/ml) was added during the last
hour. Cells were precipitated twice with ice-cold 6% trichloroacetic
acid. Cells were then removed with 0.1 N NaOH, and
radioactivity was determined by liquid scintillation counting.
Immunoblotting--
Cells were scraped in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 2.5 mM EGTA, 0.1% Tween 20, 1 mM dithiothreitol, 1 mM NaF, 0.1 mM sodium orthovanadate, 0.1 mM phenylmethylsulfonyl fluoride, 10 mM
Foci-competent 3T3/m3 Cells Show Both Inhibitory and Stimulatory
Responses to Agonist Treatment--
To study growth regulation induced
by activation of a Gq protein-coupled receptor, we
transfected NIH3T3 cells with the pTEJ8 expression vector bearing the
human m3 AchR cDNA. A clonal cell line was isolated from foci
formed in the presence of the receptor agonist carbachol (see
"Experimental Procedures"), as reported previously (4). This cell
line was designated 3T3/m3 and was further characterized. Binding
assays indicated that these cells bound 623 ± 46 fmol of
N-[3H]methylscopolamine per milligram of
protein. This corresponds to a receptor density of approximately
112,000 receptors/cell. To investigate the effects of carbachol on DNA
synthesis, 3T3/m3 cells were serum-starved for 24 h. Carbachol
treatment of these quiescent 3T3/m3 cells led to a large (22-fold over
the basal level) increase in thymidine incorporation within 24 h.
This stimulation of DNA synthesis was
concentration-dependent, with half-maximal effects observed
at 4 µM, and maximal effects observed at 1 mM carbachol (Fig. 1A).
In contrast to the effects observed in quiescent 3T3/m3 cells, when
these cells were treated with carbachol in the presence of serum,
carbachol inhibited DNA synthesis. Inhibition of DNA synthesis was
concentration-dependent, with half-maximal effects observed
at 1 µM, and maximal effects observed at 100 µM carbachol (Fig. 1B). At maximal
concentrations (100 µM), carbachol reduced DNA synthesis
to 23 ± 7% of control. Inhibitory effects of m3 AchR activation
on DNA synthesis were significant within 1 h and maximal after
12 h of carbachol treatment (Fig. 1C). At later times,
DNA synthesis rates recovered (150 ± 9.8% at 48 h). Thus, the inhibitory effect of carbachol in growing 3T3/m3 cells was transient.
To investigate the inhibitory effects of m3 AchR activation under
different growth conditions, we transfected 3T3/m3 cells with oncogenic
v-src (3T3/m3-src). Carbachol treatment of 3T3/m3-src cells led to a
concentration-dependent inhibition of
[3H]thymidine incorporation whether these cells were
growing in the presence (data not shown) or absence of serum (Fig.
2A). Significant inhibitory
effects were noted at 10 pM, half-maximal effects were observed at 0.8 µM, and maximal effects were seen with 1 mM carbachol. Treatment with 100 µM carbachol
reduced DNA synthesis significantly within 1 h. Maximal inhibition
(to 30 ± 4% of control) was observed at 12 h after
treatment (Fig. 2B). Thus, the time course of onset of
carbachol-induced inhibition of DNA synthesis was qualitatively similar
in v-src-transformed cells and in 3T3/m3 cells growing in the presence
of serum. Comparable results were also obtained in spontaneously
transformed 3T3/m3 cells and when 3T3/m3 cells were growth-stimulated
using fibroblast growth factor (data not shown).
m3 AchR Activation Stimulates ERK Phosphorylation Independently of
the Cellular Growth Context--
Because of the suggested central role
of MAPKs in G protein-activated intracellular signaling pathways, which
control cell proliferation and transformation, we investigated the
effects of carbachol on the activation of p42/p44 ERKs. Carbachol
stimulated a large increase in ERK phosphorylation within 10 min
whether 3T3/m3 cells were growing in the presence or absence of serum (Fig. 3). Carbachol also stimulated ERK
phosphorylation in 3T3/m3-src cells (data not shown). The duration of
ERK activation was longer in the serum-starved cells than in those
growing in serum or transformed with v-src. Carbachol treatment had no
effect on the ERK1/ERK2 protein levels in these cells (Fig. 3). Hence,
the opposing effects of carbachol in quiescent and growing 3T3/m3 cells
do not seem to be explainable by different effects of carbachol on the
activation of ERKs.
m3 AchR Activation Increases Cyclin D1 Levels in Quiescent Cells
but Decreases Cyclin D1 Levels in Growing Cells--
We next
investigated the effects of m3 AchR activation on cell cycle proteins.
3T3/m3 cells were either serum-starved or cultured in the presence of
serum for 24 h before treatment with carbachol for various times.
In quiescent 3T3/m3 cells, the basal levels of the G1-phase
cyclins D1 and E were low. Treatment with carbachol led to an increase
in the expression of these cyclins after 12-24 h. Carbachol also
increased the level of the cdk inhibitor p21cip1 within
1 h (Fig. 4A). The
expression of p21cip1 remained above control levels for at
least 24 h. In quiescent cells, Rb existed primarily in the
hypophosphorylated state. Carbachol treatment induced
hyperphosphorylation of Rb at the same times that the cyclin D1 and E
levels were increased. Levels of cdk4 were unaffected by carbachol
treatment (Fig. 4A).
In contrast to what was observed in the quiescent cells, in 3T3/m3
cells growing in serum, carbachol significantly decreased cyclin D1 and
E levels within 1 h (Fig. 4B). The observed decrease was transient. A maximal decrease was noted after 6 h, and after 12-24 h of carbachol treatment, cyclin D1 and E levels returned to
control levels. Carbachol induced expression of p21cip1 in
growing cells within 1 h for up to 24 h in a manner similar to that detected in the quiescent cells. Consistent with the observed time course of the carbachol-induced decrease of cyclin D1 and E
levels, treatment with carbachol led to a transient hypophosphorylation of Rb (Fig. 4B). Carbachol treatment had no effect on the
expression of cdk4. These same effects on cyclins D1 and E,
p21cip1, and Rb were also observed in 3T3/m3-src cells
(data not shown). This suggests that the carbachol-induced inhibition
of DNA synthesis is likely mediated by the effects on these cell cycle proteins.
The Carbachol-induced Increase of p21cip1 Is
PKC-dependent--
Several different pathways have been
described leading to the induction of p21cip1 expression;
some of these pathways involve PKC (17-20). PKC activity is increased
by activation of m3 AchRs. Therefore, to investigate the role of PKC in
the carbachol-induced up-regulation of p21cip1 observed in
growing 3T3/m3 cells, we tested the effects of the PKC inhibitor
GF109203X (Fig. 5). Growing 3T3/m3 cells
were pretreated with the inhibitor for 30 min and then incubated for an
additional 3 h with carbachol. Treatment with the inhibitor alone
had no effect on p21cip1 protein levels. In contrast,
GF109203X treatment completely blocked the carbachol-induced increase
in p21cip1 expression. Furthermore, incubation of the cells
for 3 h with TPA, which is known to activate PKC, mimicked the
effect of carbachol on p21cip1 expression (Fig. 5). Thus,
the observed up-regulation of p21cip1 expression by
carbachol in growing 3T3/m3 cells is likely mediated by activation of
PKC.
Carbachol-induced Decrease of Cyclin D1 Is Inhibited by Proteasome
Inhibitors--
Recently, the ubiquitin-proteasome pathway has been
shown to mediate cyclin D1 degradation (21). To investigate the
mechanisms involved in the carbachol-induced decrease of cyclin D1
levels in growing 3T3/m3 cells, we tested the effects of the proteasome inhibitors LLnL and PSI on cyclin D1 degradation. The cells were pretreated with the inhibitors for 30 min, followed by a 3-h incubation with carbachol. The carbachol-induced decrease in cyclin D1 was completely blocked by both inhibitors (Fig.
6). Thus, activation of m3AchRs likely
reduced cyclin D1 levels by activation of proteasomal degradation.
Activation of receptors, which couple to the heterotrimeric G
protein Gq, can have either stimulatory or inhibitory
effects on cell growth. These differences have previously been
attributed to differences in cell models. In the current study, we
demonstrate that activation of a Gq protein-coupled
muscarinic receptor can trigger both stimulatory and inhibitory effects
on growth in the same cell. Growth-stimulatory effects of m3 AchRs on
NIH3T3 cells are well known and have been the focus of much research
(for a review, see Ref. 12). In contrast, the current observations of
inhibitory effects of m3 AchR activation on NIH3T3 cell growth are novel.
The observation that these inhibitory effects were not noted previously
is likely explained by the fact that inhibition cannot be observed in
assays designed to assess growth stimulation. Previous work has focused
on investigating the effects of receptor activation in quiescent cells
after serum starvation. Here we examined the effects of m3 AchR
activation on growing cells. Growth was stimulated either by serum or
by transformation with v-src. In either condition, carbachol caused a
large and rapid inhibition of DNA synthesis. This suggests that the
growth-regulatory effects of m3 AchR activation depend on the growth
context of the cells. An understanding of the mechanisms involved in
these growth-inhibitory actions may provide new insight into cellular
growth regulation.
In the present study, we investigated the mechanisms involved in the
growth-inhibitory effects of m3 AchR activation. Because the ERKs are
known to be important molecules in mediating mitogenic responses, we
investigated the possibility that activation of the m3 AchR might
inhibit this pathway in growing 3T3/m3 cells. However, carbachol led to
an increase in ERK activation under all growth conditions. Differences
were noted in the duration of ERK activation in serum-fed
versus serum-starved cells. The duration of ERK activation
seems to be an important issue for proliferative responses. Recently,
Weber et al. (22) have shown that a sustained activation of
the ERKs by platelet-derived growth factor was required for continued
expression of cyclin D1 in IIC9 cells. On the other hand, Pumiglia and
Decker (23) noted that sustained stimulation of the mitogen-activated
protein kinase/extracellular signal-regulated kinase kinase/MAPK
pathway by an inducible activated form of the Raf-1 proto-oncogene
results in cell cycle arrest in NIH3T3 cells. In the current study,
inhibition of DNA synthesis was observed within 1 h, a time point
at which ERK phosphorylation was induced by carbachol under both growth
conditions. Therefore, the observed differences in the duration of
carbachol-induced ERK phosphorylation in quiescent and growing 3T3/m3
cells do not seem to be important for the observed differences in
growth regulation. The most reasonable interpretation is that the
effects of m3 AchR activation on the ERK pathway are not involved in
the inhibitory actions.
Two responses that potentially explain the growth-inhibitory effects of
m3 AchR activation are the decrease in the level of the G1
cyclin D1 and the induction of p21cip1 expression. These
two mechanisms alone or in concert would be predicted to inhibit the
phosphorylation of Rb and thereby block the entry into the S phase. The
initial time course of p21cip1 induction and cyclin D1
reduction closely paralleled the decrease in cyclin E levels and the
appearance of hypophosphorylated Rb in response to carbachol. This time
course also correlated with the observed inhibition of DNA synthesis in
3T3/m3 cells. Thus, the effects of m3 AchR activation on these cell
cycle proteins likely mediate the growth inhibition observed in 3T3/m3 cells.
p21cip1 is known as a potent cyclin-dependent
kinase inhibitor and mediator of cell growth arrest (24, 25). The
induction of p21cip1 expression by carbachol in 3T3/m3
cells was likely mediated by activation of protein kinase C because the
specific PKC inhibitor GF109203X completely blocked the increase of
p21cip1 levels. Additionally, the phorbol ester TPA
mimicked the carbachol effect and stimulated p21cip1 in a
similar manner. Previously, Yamamoto et al. (26) found that
TPA markedly inhibits DNA synthesis and proliferation of NIH3T3 cells.
This could be due, at least in part, to the induction of
p21cip1 expression demonstrated in this study. NIH3T3 cells
have been shown to express PKC- In contrast to the observed induction of cyclin D1 expression by
carbachol in quiescent cells, treatment of growing 3T3/m3 cells with
carbachol resulted in a profound decrease of cyclin D1 levels. The
D-type cyclins are the first cyclins synthesized after mitogenic
stimulation and are required and rate-limiting for G1
progression. They complex with their catalytic subunits cdk4 and cdk6,
which function as Rb kinases, and hyperphosphorylation of Rb allows the
progression through G1-S phase (30, 31). Withdrawal of
growth factors leads to a rapid cyclin D1 destruction and
G1-phase arrest (30). Decreased cyclin D1 levels have also been suggested to be involved in transforming growth factor The physiological relevance of the transforming or tumor-suppressing
abilities of these receptors is unclear. The NIH3T3 cell model suffers
from the fact that these cells are pre-neoplastic, are differentially
sensitive to transformation by different oncogenes, and can "drift"
and spontaneously assume a transformed phenotype. Expression of
Gq protein-linked receptors was not able to induce transformation in Rat-1 cells, another common model of cellular transformation (35). Furthermore, conflicting results have previously been published with regard to the effect of expressing
GTPase-deficient, constitutively active G In summary, the current study shows that Gq protein-linked
receptors couple to both inhibitory and stimulatory signaling pathways. Thus, activation of these receptors can have a variety of effects on
cell growth, depending upon the cell model, the receptor level, the
assay conditions, and the time of observation. These factors help to
explain the apparent conflicts existing in the literature with regard
to the growth effects of these receptors. An understanding of the
growth inhibitory pathways activated by these receptors may lead to
important new insights into cellular growth regulation in health and disease.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-glycerophosphate, 2 µg/ml aprotinin, and 5 µg/ml leupeptin),
sonicated, and centrifuged to remove cellular debris. Bio-Rad protein
assay reagent was used to determine the protein concentration. Samples
of 20 µg of protein denatured with Laemmli buffer were subjected to
electrophoresis on 7.5% (to detect Rb), 10% (to detect cyclin D1 and
E, cdk4, phospho- and non-phospho-ERK1/2), and 12% (to detect
p21cip1) SDS-polyacrylamide gels and transferred by
electroblotting to Hybond membranes (Amersham Pharmacia Biotech). The
blots were then incubated with the respective primary antibody, and
horseradish peroxidase-labeled secondary antibody was used for
detection with ECL (Amersham Pharmacia Biotech).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (12K):
[in a new window]
Fig. 1.
Growth stimulation and inhibition in 3T3/m3
cells isolated from receptor-bearing foci. A,
concentration dependence of carbachol-induced stimulation of DNA
synthesis in quiescent 3T3/m3 cells. 3T3/m3 cells were made quiescent
by serum starvation (24 h) and then stimulated with the indicated
concentrations of carbachol for 24 h. [3H]Thymidine
incorporation was assessed, and the results shown are expressed as the
fold of incorporation in the control cultures and represent the
mean ± S.E. for three separate experiments. Concentration
(B) and time (C) dependence of carbachol-induced
inhibition of DNA synthesis in growing 3T3/m3 cells is shown. Cells
were cultured in the presence of 10% FBS and either the indicated
concentrations of carbachol were included for 24 h (B)
or 100 µM carbachol was added for the indicated times
(C). Results shown are expressed as percentages of
control.

View larger version (15K):
[in a new window]
Fig. 2.
Inhibition of DNA synthesis in serum-deprived
3T3/m3-src cells mediated by m3 AchRs. Concentration
(A) and time (B) dependence of inhibition is
shown. 3T3/m3-src cells were cultured in the absence of growth factors
for 24 h, and the indicated concentrations of carbachol were
included for an additional 24 h (A), or 100 µM carbachol was added for the indicated times
(B). The data are presented as the percentage of
incorporation into control cultures and represent the means ± S.E. of three experiments.

View larger version (17K):
[in a new window]
Fig. 3.
Carbachol induces phosphorylation of ERKs in
quiescent and growing 3T3/m3 cells. 3T3/m3 cells were either
starved for 24 h or cultured in the presence of 10% FBS. Cells
were then incubated with (+) or without (
) 100 µM
carbachol (CCh) for the indicated times. Western blot
analysis was performed using the antibody against
anti-ACTIVETM MAPK (phospho, top
panel) or p42/p44 ERK (protein, bottom
panel).

View larger version (31K):
[in a new window]
Fig. 4.
Effects of carbachol on cell cycle proteins
in quiescent and growing 3T3/m3 cells. 3T3/m3 cells were either
serum-starved (A) for 24 h or grown in the presence of
10% FBS (B) and treated with or without 100 µM carbachol (CCh) for the indicated times,
and Western blot analysis was performed as described under
"Experimental Procedures" using the respective antibodies.
pRb, hypophosphorylated Rb; ppRb,
hyperphosphorylated Rb.

View larger version (16K):
[in a new window]
Fig. 5.
The PKC inhibitor GF109203X blocks the
carbachol-induced expression of p21cip1 in growing 3T3/m3
cells. 3T3/m3 cells were cultured in the presence of 10% FBS.
Untreated control 3T3/m3 cells (lane 1) were compared with
cells treated with carbachol (CCh; 100 µM;
3 h), GF109203X (GFX; 1 µM), or TPA (1 µM) for 3.5 h (lanes 2-4) or carbachol and
TPA together (lane 6) or with cells pretreated for 30 min
with GFX and then incubated with CCh or TPA for an additional 3 h
(lanes 5 and 7). Western blot analysis using
anti-p21cip1 is shown.

View larger version (16K):
[in a new window]
Fig. 6.
Proteasome inhibitors abolish the
carbachol-induced decrease of cyclin D1 levels in growing 3T3/m3
cells. Western blotting was performed using an anti-cyclin D1
antibody after 3T3/m3 cells growing in the presence of 10% FBS were
not treated (control, lane 1) or were treated
with carbachol (CCh; 100 µM, 3 h), LLnL
(100 µM), or PSI (100 µM) for 3.5 h
(lanes 2, 3, and 5) or treated for 3 h with
carbachol and the respective inhibitor together, after a 30-min
inhibitor pretreatment (lanes 4 and 6).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and PKC-
isozymes (6). The
atypical PKC-
, which is not activated by either Ca2+ or
diacylglycerol in vitro, has not been described to be
involved in growth regulation. However, the classical
-isoform of
PKC has been shown to raise p21cip1 levels and induce
growth arrest in a human epithelial cell line (27). Stimulation of m3
AchRs increases PKC activity via accumulation of diacylglycerol
generated by G
q -mediated activation of phospholipase C-
. Taken together, the data support an intracellular pathway leading to the observed p21cip1 induction by carbachol in
3T3/m3 cells that involves a G
q/PLC-
-induced activation of PKC
. The temporal pattern of p21cip
induction did not correlate with the reversal of growth inhibition. Furthermore, p21cip1 induction was also observed when
quiescent 3T3/m3 cells were treated with carbachol, which resulted in a
stimulation of growth. Thus, the data do not support the hypothesis
that induction of p21cip1 is the sole inhibitory mechanism
activated by m3 AchR activation. p21cip1 is found in active
cyclin/cdk complexes in proliferating cells such that the stoichiometry
between p21cip1 and cyclin/cdk complexes determines the
cell cycle-inhibitory behavior of p21cip1 (25, 28, 29).
Hence, p21cip1 may be involved in the initial inhibitory
effect, but subsequent changes in the stoichiometry of other cell cycle
proteins may overcome this effect.
-induced (32), rapamycin-induced (33), and cyclic AMP-induced (34) growth
inhibition. We observed a rapid decrease in cyclin D1 after carbachol
treatment of growing 3T3/m3 cells. Diehl et al. (21) suggested that a ubiquitin-proteasome pathway mediates cyclin D1
degradation. In the current study, proteasome inhibitors completely blocked carbachol-induced cyclin D1 degradation. The mechanisms involved in targeting cyclin D1 for ubiquitin-proteasome-mediated degradation are unknown. The carbachol-induced decrease in cyclin D1
was transient, and levels returned to control levels within 24 h.
The time course of cyclin D1 degradation closely paralleled the
observed inhibition of DNA synthesis. Thus, the effects of m3 AchR
activation on cyclin D1 levels could explain both the initiation and
the reversal of the observed effects on DNA synthesis. Further
investigation will be necessary to understand the mechanisms involved
in the effects of m3 AchR activation on cyclin D1.
q subunits in
NIH3T3 cells. Wu et al. (36) observed that mutant active
G
q and G
11 subunits caused cell death
when transfected into NIH3T3 cells. In contrast, others have reported
that constitutively active G
q could transform NIH3T3 cells (37, 38). Although it was reported that expression of the active
G
q mutant caused more cell death than oncogenic
transformation in NIH3T3 cells, this was interpreted to mean that
low-level expression resulted in transformation and higher levels of
expression caused cell death (38). Therefore, it is unclear how
widespread or important the transforming effects might be. Another
limitation to the ability of these receptors to mediate cellular
transformation would likely be the requirement for sustained high
concentrations of agonist. An alternative to high concentrations of
agonist would be mutations that lead to persistent activation of the
receptor or the G proteins. Mutant forms of G
q or other
members of the G
q subunit family or receptors that
couple to these G proteins have not been identified to date in any
tumors or genetic disorder. If this pathway were highly transforming,
then one would expect to find numerous examples, considering the
ubiquitous nature of these receptors.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Drs. Jessica Schwartz, Ormond MacDougald, and Paul Cook for critical review of the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant DK41225 and Michigan Gastrointestinal Peptide Center Grant DK34933.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
These authors contributed equally to this report.
§ To whom correspondence should be addressed: Box 0622, Dept. of Physiology, The University of Michigan, 1150 W. Medical Center Dr., Ann Arbor, MI 48109. Tel.: 734-763-2539; Fax: 734-936-8813; E-mail: CLogsdon@umich.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: m3 AchR, m3 muscarinic receptor for acetylcholine; cdk, cyclin-dependent kinase; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; PKC, protein kinase C; Rb, retinoblastoma gene product; TPA, 12-O-tetradecanoylphorbol-13-acetate; FBS, fetal bovine serum.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Jackson, T. R., Blair, L. A., Marshall, J., Goedert, M., and Hanley, M. R. (1988) Nature 335, 437-440[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Parma, J., Duprez, L., Van Sande, J., Cochaux, P., Gervy, C., Mockel, J., Dumont, J., and Vassart, G. (1993) Nature 365, 649-651[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Shenker, A., Laue, L., Kosugi, S., Merendino, J. J. J., Minegishi, T., and Cutler, G. B., Jr. (1993) Nature 365, 652-654[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Gutkind, J. S.,
Novotny, E. A.,
Brann, M. R.,
and Robbins, K. C.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
4703-4707 |
| 5. |
Mattingly, R. R.,
Sorisky, A.,
Brann, M. R.,
and Macara, I. G.
(1994)
Mol. Cell. Biol.
14,
7943-7952 |
| 6. | Stephens, E. V., Kalinec, G., Brann, M. R., and Gutkind, J. S. (1993) Oncogene 8, 19-26[Medline] [Order article via Infotrieve] |
| 7. |
Felder, C. C.,
MacArthur, L.,
Ma, A. L.,
Gusovsky, F.,
and Kohn, E. C.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
1706-1710 |
| 8. |
Detjen, K.,
Yang, J.,
and Logsdon, C. D.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
10929-10933 |
| 9. | Detjen, K., Fenrich, M., and Logsdon, C. D. (1997) Gastroenterology 112, 952-959[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Gutkind, J. S., and Robbins, K. C. (1992) Biochem. Biophys. Res. Commun. 188, 155-161[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Felder, C. C. (1995) FASEB J. 9, 619-625[Abstract] |
| 12. |
Gutkind, J. S.
(1998)
J. Biol. Chem.
273,
1839-1842 |
| 13. | Dhanasekaran, N., Tsim, S. T., Dermott, J. M., and Onesime, D. (1998) Oncogene 17, 1383-1394[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Xu, N., McCormick, F., and Gutkind, J. S. (1994) Oncogene 9, 597-601[Medline] [Order article via Infotrieve] |
| 15. | Peeper, D. S., Upton, T. M., Ladha, M. H., Neuman, E., Zalvide, J., Bernards, R., DeCaprio, J. A., and Ewen, M. E. (1997) Nature 386, 177-181[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Yang, J., Logsdon, C. D., Johansen, T. E., and Williams, J. A. (1993) Mol. Pharmacol. 44, 1158-1164[Abstract] |
| 17. |
Datto, M. B., Yu, Y.,
and Wang, X. F.
(1995)
J. Biol. Chem.
270,
28623-28628 |
| 18. | Li, R., Hannon, G. J., Beach, D., and Stillman, B. (1996) Curr. Biol. 6, 189-199[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Sherr, C. J.,
and Roberts, J. M.
(1995)
Genes Dev.
9,
1149-1163 |
| 20. | Livneh, E., and Fishman, D. D. (1997) Eur. J. Biochem. 248, 1-9[Medline] [Order article via Infotrieve] |
| 21. |
Diehl, J. A.,
Zindy, F.,
and Sherr, C. J.
(1997)
Genes Dev.
11,
957-972 |
| 22. | Weber, J. D., Raben, D. M., Phillips, P. J., and Baldassare, J. J. (1997) Biochem. J. 326, 61-68 |
| 23. |
Pumiglia, K. M.,
and Decker, S. J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
448-452 |
| 24. | Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. (1993) Nature 366, 701-704[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. (1993) Cell 75, 805-816[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Yamamoto, T.,
Tsuda, T.,
Hamamori, Y.,
Nishimura, N.,
and Takai, Y.
(1988)
J. Biochem. (Tokyo)
104,
53-56 |
| 27. |
Frey, M. R.,
Saxon, M. L.,
Zhao, X.,
Rollins, A.,
Evans, S. S.,
and Black, J. D.
(1997)
J. Biol. Chem.
272,
9424-9435 |
| 28. |
Zhang, H.,
Hannon, G. J.,
and Beach, D.
(1994)
Genes Dev.
8,
1750-1758 |
| 29. | Hiyama, H., Iavarone, A., LaBaer, J., and Reeves, S. A. (1997) Oncogene 14, 2533-2542[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Sherr, C. J. (1993) Cell 73, 1059-1065[Medline] [Order article via Infotrieve] |
| 31. |
Matsushime, H.,
Quelle, D. E.,
Shurtleff, S. A.,
Shibuya, M.,
Sherr, C. J.,
and Kato, J. Y.
(1994)
Mol. Cell. Biol.
14,
2066-2076 |
| 32. | Ko, T. C., Yu, W., Sakai, T., Sheng, H., Shao, J., Beauchamp, R. D., and Thompson, E. A. (1998) Oncogene 16, 3445-3454[CrossRef][Medline] [Order article via Infotrieve] |
| 33. |
Hashemolhosseini, S.,
Nagamine, Y.,
Morley, S. J.,
Desrivieres, S.,
Mercep, L.,
and Ferrari, S.
(1998)
J. Biol. Chem.
273,
14424-14429 |
| 34. | L'Allemain, G., Lavoie, J. N., Rivard, N., Baldin, V., and Pouyssegur, J. (1997) Oncogene 14, 1981-1990[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Kahan, C., Julius, D., Pouyssegur, J., and Seuwen, K. (1992) Exp. Cell Res. 200, 523-527[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Wu, D. Q.,
Lee, C. H.,
Rhee, S. G.,
and Simon, M. I.
(1992)
J. Biol. Chem.
267,
1811-1817 |
| 37. |
De Vivo, M.,
and Iyengar, R.
(1994)
J. Biol. Chem.
269,
19671-19674 |
| 38. |
Kalinec, G.,
Nazarali, A. J.,
Hermouet, S.,
Xu, N.,
and Gutkind, J. S.
(1992)
Mol. Cell. Biol.
12,
4687-4693 |
This article has been cited by other articles:
![]() |
S. H. Shafer and C. L. Williams Elevated Rac1 Activity Changes the M3 Muscarinic Acetylcholine Receptor-Mediated Inhibition of Proliferation to Induction of Cell Death Mol. Pharmacol., May 1, 2004; 65(5): 1080 - 1091. [Abstract] [Full Text] |
||||
![]() |
K. Cheng, P. Zimniak, and J.-P. Raufman Transactivation of the Epidermal Growth Factor Receptor Mediates Cholinergic Agonist-Induced Proliferation of H508 Human Colon Cancer Cells Cancer Res., October 15, 2003; 63(20): 6744 - 6750. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pearson, M. Catsicas, D. Becker, and P. Mobbs Purinergic and Muscarinic Modulation of the Cell Cycle and Calcium Signaling in the Chick Retinal Ventricular Zone J. Neurosci., September 1, 2002; 22(17): 7569 - 7579. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Dumont, S. Dremier, I. Pirson, and C. Maenhaut Cross signaling, cell specificity, and physiology Am J Physiol Cell Physiol, July 1, 2002; 283(1): C2 - C28. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Varro, P J Noble, L E Wroblewski, L Bishop, and G J Dockray Gastrin-cholecystokininB receptor expression in AGS cells is associated with direct inhibition and indirect stimulation of cell proliferation via paracrine activation of the epidermal growth factor receptor Gut, June 1, 2002; 50(6): 827 - 833. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |